Belite Bio, Inc
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Belite Bio, Inc now
Current reporting with the operating signal separated from the noise.
Belite Bio, Inc: Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
The story matters when it changes Belite Bio, Inc’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Belite Bio, Inc (NASDAQ:BLTE) Q1 2026 Earnings Call Transcript
Investors are testing whether Belite Bio, Inc’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference Transcript
The story matters when it changes Belite Bio, Inc’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Belite Bio, Inc (NASDAQ:BLTE) Q3 2025 Earnings Call Transcript
Investors are testing whether Belite Bio, Inc’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Prepared Remarks Transcript
The story matters when it changes Belite Bio, Inc’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Belite Bio, Inc. Files Annual Report on Form 20-F for Year Ended December 31, 2024
The story matters when it changes Belite Bio, Inc’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Belite Bio, Inc. Announces $15 Million Registered Direct Offering of American Depositary Shares
Investors are testing whether Belite Bio, Inc’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Belite Bio, Inc. ADR (BLTE) Gets a Buy from Benchmark Co.
The story matters when it changes Belite Bio, Inc’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest BLTE filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Belite Bio, Inc, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →